FusionPathway: Prediction of pathways and therapeutic targets associated with gene fusions in cancer
Fig 4
Prediction evaluation of two undruggable fusions in sarcoma using benchmark gene sets.
(A) EWS-FLI1 fusion. (B) FUS-DDIT3 fusion. Target gene sets of identified sensitive compounds of Ewing sarcoma and Myxoid liposarcoma in high-throughput screening assay are denoted drug screening. Other benchmark gene sets have similar denotations as Fig 2.